---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-033767"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:33:32.048238+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roivant reports ~80% durability and ~50% ATD-free remission in Graves' disease data

## Summary
- Of 21 patients in 6-month off-treatment follow-up, ~80% (17/21) maintained normal thyroid function.
- ~50% of responders (8/17) achieved anti-thyroid drug-free remission after 6 months off batoclimab.
- Two registrational trials for IMVT-1402 in Graves' disease are enrolling; topline data expected 2027.
- Safety consistent with prior batoclimab studies; first potential disease-modifying therapy for uncontrolled GD.
- Roivant and Immunovant to host investor call Sept 3, 2025 at 4:30 p.m. EDT to discuss data.

## SEC filing metadata
- accession: 0001140361-25-033767
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036125033767/0001140361-25-033767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036125033767/ef20055076_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-033767
- JSON: https://secwatch.observer/filing/0001140361-25-033767.json
- Plain text: https://secwatch.observer/filing/0001140361-25-033767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.